Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. It is characterized by an accumulation of B-lymphocytes in peripheral blood (PB), bone marrow (BM), lymph nodes (LN) and spleen. Tissue involvement is strongly associated with disease progression and aggressiveness. ...
Acute myeloid leukemia prognosis appears to be associated with CLL-1, on the basis of the information previously mentioned. In a study published in 2017, Yan-Yu Wang et al. utilized a 42.5% cutoff expression level to divide 123 bone marrow samples from CD34 + AML patients into low and...
Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukemia Br J Haematol, 168 (2015), pp. 153-156 CrossrefGoogle Scholar 19. International CLL-IPI working group An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysi...
Bomben R, Dal Bo M, Zucchetto A, Zaina E, Nanni P, Sonego P, Del Poeta G, Degan M, Gattei V: Mutational status of IgVH genes in B-cell chronic lymphocytic leukemia and prognosis: percent mutations or antigen-driven selection? Leukemia 2005, 19: 1490–1492....
39 However, we do not recommend FCR given the availability of alternative effective treatment options, as well as prolonged immunosuppression and secondary cancers associated with FCR, with secondary myelodysplasia/acute myeloid leukemia occurring in ∼5% of patients. 2.2. When initial treatment of ...
Clinical observation without therapy—defined as “watch and wait” (W&W)—has been the gold standard for the management of early-stage chronic lymphocytic leukemia (CLL). This principle is based on the repeated failure of previous attempts to improve the clinical outcome of CLL patients by early...
Ibrutinib is a first-in-class oral irreversible inhibitor of BTK indicated for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma in adults. Ibrutinib has transformed the landscape of CLL treatment, and the introduction of ibrutinib for CLL treatment marked the ...
PROGNOSISCHRONIC lymphocytic leukemiaNUCLEOTIDE sequencingSURVIVAL rateCHRONIC leukemiaPROGNOSTIC modelsChronic lymphocytic leukemia (CLL) is a low-grade B-cell lymphoproliferative disorder. It is the most prevalent type of leukemia in the western countries, with a median age at diagnosis ...
NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLLdoi:10.3324/haematol.2011.060129chronic lymphocytic leukemiaNOTCH1 mutations...
In the revised National Cancer Institute Working Group (NCI-WG)/International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines for CLL, CLL-like monoclonal B lymphocytosis (MBL) is defined as the presence of less than 5 × 109/L B lymphocytes in the peripheral blood. However, the ...